Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Latest PR Push: Protecting the Reputation of Generic Drugs

This article was originally published in RPM Report

Executive Summary

The public’s acceptance of generic drugs is at an all-time high. But manufacturing issues, shortages of life-saving medications and questions about the overall quality of generics are testing the system like never before. FDA’s tough love message to industry: fix the manufacturing problems—or risk your reputation.

Advertisement

Related Content

Growing Pains for Generic Drugs: OGD Gains Respect, But Loses Geba
FDA Generics Research Forges Ahead After Agency’s Bupropion Mea Culpa
Drug Shortages Endgame: FDA Goes On Offensive As Legislative Plot Thickens
Drug Shortage Provisions In Draft PDUFA Bill Would Expedite Major Manufacturing Changes
FDA’s Drug Shortage Reg Adds More Manufacturers, Products To Notification List
ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics
To Prevent Drug Shortages, Don't Look To Inspections, FDA Says
FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution
FDA Aims To Bolster Generics' Image With Research, Regulatory Changes
Teva’s Generic Bupropion XL Meets Bioequivalence To Wellbutrin XL, FDA Finds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080985

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel